Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/27/2025

Vancomycin Dosing and Monitoring for CRBSI

Initial Dosing Strategy

  • For patients with CRBSI and normal renal function, the Infectious Diseases Society of America recommends administering vancomycin 15-20 mg/kg (actual body weight) every 8-12 hours, not exceeding 2 g per dose, targeting trough concentrations of 15-20 μg/mL 1, 2
  • A loading dose of 25-30 mg/kg (actual body weight) is recommended for seriously ill patients with suspected CRBSI, as this represents a severe bloodstream infection requiring rapid therapeutic levels 1, 2, 3
  • The loading dose is not affected by renal function—only maintenance doses require adjustment 3

Therapeutic Monitoring Requirements

  • The target trough concentrations for CRBSI are 15-20 μg/mL, which correlates with an AUC/MIC ratio ≥400 1, 2, 3
  • Trough levels should be obtained at steady state, prior to the fourth or fifth dose 1, 2
  • Mandatory trough monitoring is recommended for all patients with CRBSI given the severity of infection 1, 2

Treatment Duration and Catheter Management

  • The American College of Oncology recommends that most CRBSI cases require 10-14 days of treatment 4, 5
  • The treatment duration can be extended to 4-6 weeks if persistent bacteremia/fungemia continues >72 hours after catheter removal, or if complicated by endocarditis or suppurative thrombophlebitis 6, 7
  • Catheter removal is indicated for severe sepsis, suppurative thrombophlebitis, endocarditis, tunnel infection, port abscess, BSI continuing despite 48-72 hours of adequate therapy, or infections with S. aureus, fungi, or mycobacteria 4, 5

Empirical Coverage Considerations

  • Vancomycin is recommended as empirical treatment for suspected CRBSI before culture results are available 4, 5
  • If severe symptoms are present, empirical anti-Gram-negative coverage (fourth-generation cephalosporin, carbapenem, or β-lactam/β-lactamase combination) should be added 4, 5
  • Daptomycin can be considered in cases of higher nephrotoxicity risk or high prevalence of MRSA strains with vancomycin MIC ≥2 μg/mL 4, 5

Special Population: Hemodialysis Patients with CRBSI

  • For hemodialysis patients with CRBSI, the Clinical Infectious Diseases society recommends administering 20 mg/kg (actual body weight) after each dialysis session, rounded to the nearest 500-mg increment 6, 7, 9
  • Antibiotic lock therapy can be used as adjunctive therapy after each dialysis session for 10-14 days if catheter is retained 6, 7, 9